Fortress Biotech, Inc.
FBIO
$2.76
$0.072.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.29M | 56.90M | 56.78M | 56.68M | 62.50M |
| Total Other Revenue | 3.01M | 2.40M | 1.00M | 1.00M | 19.00M |
| Total Revenue | 62.30M | 59.30M | 57.78M | 57.68M | 81.50M |
| Cost of Revenue | 39.93M | 47.89M | 53.22M | 75.33M | 79.48M |
| Gross Profit | 22.37M | 11.41M | 4.56M | -17.66M | 2.02M |
| SG&A Expenses | 105.01M | 109.59M | 91.65M | 83.93M | 77.08M |
| Depreciation & Amortization | 6.62M | 6.37M | 6.12M | 5.87M | 6.21M |
| Other Operating Expenses | -4.55M | -4.55M | -4.55M | -4.55M | -- |
| Total Operating Expenses | 147.00M | 159.29M | 146.44M | 160.58M | 162.77M |
| Operating Income | -84.70M | -99.99M | -88.65M | -102.90M | -81.27M |
| Income Before Tax | -53.47M | -88.95M | -106.12M | -120.45M | -123.08M |
| Income Tax Expenses | 362.00K | 405.00K | 405.00K | 405.00K | 448.00K |
| Earnings from Continuing Operations | -53.83 | -89.35 | -106.52 | -120.86 | -123.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 57.82M | 74.62M | 65.36M | 74.86M | 75.01M |
| Net Income | 3.99M | -14.73M | -41.16M | -46.00M | -48.51M |
| EBIT | -84.70M | -99.99M | -88.65M | -102.90M | -81.27M |
| EBITDA | -80.07M | -95.56M | -84.19M | -98.44M | -76.74M |
| EPS Basic | -0.22 | -1.12 | -2.34 | -2.90 | -3.58 |
| Normalized Basic EPS | 0.68 | 0.21 | 0.18 | 0.19 | 1.30 |
| EPS Diluted | -0.29 | -1.17 | -2.35 | -2.91 | -3.58 |
| Normalized Diluted EPS | 0.59 | 0.20 | 0.18 | 0.19 | 1.30 |
| Average Basic Shares Outstanding | 106.59M | 99.04M | 90.48M | 81.18M | 65.92M |
| Average Diluted Shares Outstanding | 115.39M | 101.98M | 90.48M | 81.18M | 65.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | 0.00% | -4.88% | -8.73% | -12.42% |